主页 > 医学文档 >
【drug-news】combo药能有效治疗肾癌
Drug combo effective for kidney cancer
Targeted therapies before surgery could help prolong lives, researchers say
Updated: 10:39 a.m. ET Nov. 9, 2006
LONDON - Treating patients with advanced kidney cancer before surgery with a combination of targeted therapies is safe, effective and may prolong their lives, researchers said on Thursday.
Scientists at the University of Texas MD Anderson Cancer Centre, who presented their findings at a conference in Prague, studied the effect of giving the drugs bevacizumab and erlotinib to patients before their tumour was removed.
“The main aim of this study was to look at the efficacy and safety of using these targeted therapies before surgery, and our results have shown that there were few side effects and that it prolonged the survival of our patients,” said Eric Jonasch, a professor of medicine at the university.
Story continues below ↓
--------------------------------------------------------------------------------
advertisement
--------------------------------------------------------------------------------
Other studies have focused on the impact of giving the drug combo to patients after surgery but Jonasch and his team said their trial of 20 patients is the first to investigate the pre-surgical effect.
Bevacizumab, which is sold under the name Avastin, was developed by U.S. biotech group Genentech and its partner Roche Holding AG. It is an anti-angiogenesis drug which starves the tumour of blood supply.
Click for related content
Eating fatty fish may ward off kidney cancer
Erlotinib, which is marketed by Roche as Tarceva, is a drug that blocks a signal which tells cells to divide.
“Our findings indicate that this treatment approach might be applicable to a wide range of patients with renal cell carcinoma (kidney cancer) and that we might be able to use systemic treatment, before surgery, to treat many more people with metastatic disease successfully,” Jonasch said in a statement.
The patients received bevacizumab intravenously once every two weeks for four weeks and took erlotinib orally every day for eight weeks before they had surgery.
Each year, 190,000 people are diagnosed with kidney cancer. Most cases occur in developed countries and the disease is twice as common in men than women. If the cancer has spread to the lymph nodes or other organs, the five-year survival rate is very low.
Copyright 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. 本人认领此篇翻译，48小时内未提交译文，其他战友请自由认领 过了48小时啦，本人认领 试译 请多指教！
联合用药能有效治疗肾癌
研究人员称：术前进行靶向给药治疗有助延长患者生命。
2006年11月9日东部时间 上午10:39最新消息
伦敦 对晚期肾癌患者在术前施以靶向联合给药治疗，安全、有效 并且能延长患者生命，星期四研究人员如是说。
在肿瘤移除术前，对患者给予贝伐单抗合并埃罗替尼治疗，德州大学安得森癌症研究中心的科学家们对此种方法的治疗效果进行了研究，并在布拉格学术研讨会上公布了他们的发现。
“此项研究主要在于观察患者术前应用靶向给药治疗的有效性和安全性，结果显示此种治疗方法副作用少，延长了患者的生命。”该校医学院的Eric Jonasch教授说。
广告之后，接上文。
此前的研究大都关注术后而非术前对患者进行联合给药的治疗效果，而Jonasch教授及其团队称，他们对这20名患者所做的实验是首次对术前治疗效果的研究。
贝伐单抗（商品名：阿瓦斯丁，Avastin）由美国生物技术Genentech集团及罗氏药业合作开发，是一种用以阻断肿瘤血供的血管新生抑制剂。
相关连接：
吃鱼油远离肾癌
由罗氏公司以商品名Tarceva上市的埃罗替尼，是一种阻断细胞分裂信号的药物。
“这一发现预示这种治疗手段对肾细胞癌（肾癌）患者的应用范围很广，在术前，我们可能对更多的转移患者进行成功的系统治疗。” Jonasch在综述中说道。
在术前，患者每两周一次静脉接受贝伐单抗，持续四周；同时，每天口服埃罗替尼，持续八周。
每年，有190,000人被诊断为肾癌。多数病例在发达国家，并且男性的发病率为女性的两倍。如果癌症扩展到淋巴结或其他器官，则五年生存率很低。
版权归路透社所有，未经许可不得转载。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-06 17:11
医学,生命科学网